Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07149363 · ClinicalTrials.gov registry record · Phase 2

Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer

A Phase 2 study of Small Cell Lung Cancer (SCLC), sponsored by Alliance Foundation Trials.

Recruiting
Registry status
Phase 2
Development phase
65
Enrollment target
1
Study location

NCT07149363 is a Phase 2 study of Small Cell Lung Cancer (SCLC) that is actively recruiting participants, run by Alliance Foundation Trials. The registered enrollment target is 65 participants, below the 357-participant average among 9 other Small Cell Lung Cancer (SCLC) trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07149363, a Phase 2 study of Small Cell Lung Cancer (SCLC), is actively recruiting participants, sponsored by Alliance Foundation Trials.

RECRUITING
Registry status
Phase 2
Development phase
65 participants
Enrollment target
1
Study location

Study Summary

This is a phase II trial of adjuvant chemotherapy and immunotherapy for completely resected small cell lung cancer (SCLC).

Conditions Studied

Small Cell Lung Cancer (SCLC)

Interventions

  • DRUG Durvalumab 50 MG/ML

Study Locations (1)

Virginia

  • University of Virginia Comprehensive Cancer Center - Charlottesville

Trial Details

FieldValue
Enrollment Target 65 participants
Start Date 2026-02
Est. Completion 2031-02
Phase Phase 2

Sponsor

Alliance Foundation Trials

20 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07149363

The ClinicalTrials.gov registry entry for NCT07149363 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 357-participant average among 9 other Small Cell Lung Cancer (SCLC) trials with a reported enrollment target (82% lower). The listed sponsor is Alliance Foundation Trials, which has 20 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Small Cell Lung Cancer (SCLC) appearing as the primary indexed condition, and to 1 intervention - of which Durvalumab 50 MG/ML is the first listed.

NCT07149363 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.

Frequently Asked Questions

What is clinical trial NCT07149363 about?

NCT07149363 is a clinical study titled "Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer". This is a phase II trial of adjuvant chemotherapy and immunotherapy for completely resected small cell lung cancer (SCLC).

What is the current status of trial NCT07149363?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2026-02. Estimated completion is 2031-02.

What conditions does trial NCT07149363 study?

This clinical trial studies the following conditions: Small Cell Lung Cancer (SCLC).

What interventions are being tested in trial NCT07149363?

The interventions under investigation include: Durvalumab 50 MG/ML (DRUG).

Who is sponsoring clinical trial NCT07149363?

This trial is sponsored by Alliance Foundation Trials, which has 20 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07149363 being conducted?

This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Small Cell Lung Cancer (SCLC)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Small Cell Lung Cancer (SCLC)

All registered trials for this condition

Virginia

All trials with a study site in Virginia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.